Immune checkpoint receptors, such as TIGIT, PD-1 and CTLA-4, have been discovered to be highly expressed in numerous types of cancer, and they are currently being targeted to improve antitumor and T or NK cell responses (33, 34). Here, CTLA4 is linked to cancer.